Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.
The natural history for inhalational Bacillus anthracis (Ames strain) exposure in New Zealand white rabbits was investigated to better identify potential, early biomarkers of anthrax. Twelve SPF Bordetella-free rabbits were exposed to 150 LD(50) aerosolized B. anthracis spores, and clinical signs, body temperature, complete blood count, bacteremia, and presence of protective antigen in the blood (that is, antigenemia) were examined. The development of antigenemia and bacteremia coincided and preceded both pyrexia and inversion of the heterophil:lymphocyte ratio, an indicator of infection. Antigenemia was determined within 1 h by electrochemiluminescence immunoassay, compared with the 24-h traditional culture needed for bacteremia determination. Rabbits appeared clinically normal until shortly before succumbing to anthrax approximately 47 h after challenge or approximately 22 h after antigenemia, which suggests a relatively narrow therapeutic window of opportunity. To evaluate the therapeutic rabbit model, B. anthracis-exposed rabbits were treated (after determination of antigenemia and later confirmed to be bacteremic) intravenously with the fluoroquinolone antibiotic levofloxacin for 5 d at a total daily dose of 25 or 12.5 mg/kg, resulting in nearly 90% and 70% survival, respectively, to the study end (28 d after challenge). The peak level for 12.5 mg/kg was equivalent to that observed for a 500-mg daily levofloxacin dose in humans. These results suggest that intravenous levofloxacin is an effective therapeutic against inhalational anthrax. Taken together, our findings indicate that antigenemia is a viable and early biomarker for B. anthracis infection that can be used as a treatment trigger to allow for timely intervention against this highly pathogenic disease.
Center for Aerobiological Sciences, United States Army Medical Institute of Infectious Diseases, Fort Detrick, Maryland, USA. steven.yee@us.army.mil
Steven B
SB
Yee
Joshua M
JM
Hatkin
David N
DN
Dyer
Steven A
SA
Orr
M Louise M
ML
Pitt
D000336:Aerosols; D000818:Animals; D000881:Anthrax / Q000175:diagnosis / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000097:blood; D001408:Bacillus anthracis / Q000276:immunology; D016470:Bacteremia / Q000175:diagnosis / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D005260:Female; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D013171:Spores, Bacterial; D013997:Time Factors
D000336:Aerosols; D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D015415:Biomarkers; D064704:Levofloxacin; D015242:Ofloxacin
Comp Med. 2009 Jun;59(3):257-65
19619416
Clin Invest Med. 1988 Aug;11(4):297-303
3168352
Vet Pathol. 2007 Sep;44(5):716-21
17846250
Infect Immun. 2006 Oct;74(10):5871-6
16988266
Rev Physiol Biochem Pharmacol. 2004;152:135-64
15549606
Antimicrob Agents Chemother. 2005 Dec;49(12):5099-106
16304178
Mod Pathol. 2001 May;14(5):482-95
11353060
Clin Chem. 1989 Aug;35(8):1777-9
2758652
Infect Immun. 2008 Dec;76(12):5790-801
18852240
Emerg Infect Dis. 2001 Nov-Dec;7(6):933-44
11747719
J Clin Pathol. 2003 Mar;56(3):182-7
12610093
Science. 1998 May 1;280(5364):734-7
9563949
Future Microbiol. 2006 Dec;1(4):397-415
17661631
J Microbiol Methods. 2003 Sep;54(3):295-313
12842477
JAMA. 2002 May 1;287(17):2236-52
11980524
Antimicrob Agents Chemother. 2002 Jul;46(7):2307-9
12069996
J Pharmacol Toxicol Methods. 2004 Jan-Feb;49(1):39-55
14670693
J Biol Chem. 1993 Feb 15;268(5):3334-41
8429009
Ann Intern Med. 2006 Feb 21;144(4):270-80
16490913
J Am Vet Med Assoc. 1989 Oct 1;195(7):981-6
2529233
Arch Pathol Lab Med. 1998 Nov;122(11):982-92
9822127
Clin Infect Dis. 2007 Apr 1;44(7):968-71
17342650
Appl Environ Microbiol. 2009 Oct;75(19):6157-67
19648366
Expert Rev Anti Infect Ther. 2003 Oct;1(3):371-87
15482135
Antimicrob Agents Chemother. 2006 Nov;50(11):3535-42
17065619
J Appl Microbiol. 2006 Sep;101(3):594-606
16907809
Obstet Gynecol. 1998 Jul;92(1):28-30
9649087
Infect Immun. 2007 Jun;75(6):2689-98
17353290
Microbiol Mol Biol Rev. 2004 Dec;68(4):617-29
15590776
J Infect Dis. 1987 Nov;156(5):849-50
3655405
N Engl J Med. 2009 Jul 9;361(2):135-44
19587338
Expert Rev Anti Infect Ther. 2007 Aug;5(4):665-84
17678429
Infect Immun. 1988 Jul;56(7):1807-13
3384478
Mol Aspects Med. 2009 Dec;30(6):467-80
19665473
Microbes Infect. 1999 Feb;1(2):131-9
10594977
Ann N Y Acad Sci. 1980;353:83-93
7013615
Cell Microbiol. 2007 Mar;9(3):555-65
17223930
Pharm Res. 2006 Feb;23(2):262-9
16319999
Emerg Infect Dis. 2002 Oct;8(10):1019-28
12396909
J Biol Chem. 1971 May 25;246(10):3189-95
4995746
Emerg Infect Dis. 2008 Apr;14(4):
18394267
J Comp Pathol. 2007 Feb-Apr;136(2-3):156-66
17374379